Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists

Brent N. Rexer, Jeffrey A. Engelman, Carlos L. Arteaga

Research output: Contribution to journalReview article

58 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors (TKIs) are effective anti-cancer therapies but resistance to these agents eventually develops. Several models of resistance to TKIs have been studied including resistance to EGFR inhibitors. Recent studies in EGFR-dependent A431 cells found upregulation of the IGF1R pathway as a mechanism to overcome blockade of EGFR. This was associated with amplification of IGF1R signaling and recovery of downstream PI3K-AKT activation. This work adds to a growing body of cell lines in culture that have provided insights into mechanisms of resistance that can be interrogated in primary tumors in patients. In this review, these model systems and their applicability to human cancers, as well as strategies to identify and overcome resistance to TKIs, are discussed.

Original languageEnglish (US)
Pages (from-to)18-22
Number of pages5
JournalCell Cycle
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Protein-Tyrosine Kinases
Neoplasms
Phosphatidylinositol 3-Kinases
Up-Regulation
Cell Line
Therapeutics

Keywords

  • Breast cancer
  • EGFR
  • HER2
  • PI3K
  • TKI resistance
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this

Overcoming resistance to tyrosine kinase inhibitors : Lessons learned from cancer cells treated with EGFR antagonists. / Rexer, Brent N.; Engelman, Jeffrey A.; Arteaga, Carlos L.

In: Cell Cycle, Vol. 8, No. 1, 01.01.2009, p. 18-22.

Research output: Contribution to journalReview article

@article{3b1fb223cbaa437c8a9f36ac0d8bf4af,
title = "Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists",
abstract = "Tyrosine kinase inhibitors (TKIs) are effective anti-cancer therapies but resistance to these agents eventually develops. Several models of resistance to TKIs have been studied including resistance to EGFR inhibitors. Recent studies in EGFR-dependent A431 cells found upregulation of the IGF1R pathway as a mechanism to overcome blockade of EGFR. This was associated with amplification of IGF1R signaling and recovery of downstream PI3K-AKT activation. This work adds to a growing body of cell lines in culture that have provided insights into mechanisms of resistance that can be interrogated in primary tumors in patients. In this review, these model systems and their applicability to human cancers, as well as strategies to identify and overcome resistance to TKIs, are discussed.",
keywords = "Breast cancer, EGFR, HER2, PI3K, TKI resistance, Tyrosine kinase inhibitors",
author = "Rexer, {Brent N.} and Engelman, {Jeffrey A.} and Arteaga, {Carlos L.}",
year = "2009",
month = "1",
day = "1",
doi = "10.4161/cc.8.1.7324",
language = "English (US)",
volume = "8",
pages = "18--22",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Overcoming resistance to tyrosine kinase inhibitors

T2 - Lessons learned from cancer cells treated with EGFR antagonists

AU - Rexer, Brent N.

AU - Engelman, Jeffrey A.

AU - Arteaga, Carlos L.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Tyrosine kinase inhibitors (TKIs) are effective anti-cancer therapies but resistance to these agents eventually develops. Several models of resistance to TKIs have been studied including resistance to EGFR inhibitors. Recent studies in EGFR-dependent A431 cells found upregulation of the IGF1R pathway as a mechanism to overcome blockade of EGFR. This was associated with amplification of IGF1R signaling and recovery of downstream PI3K-AKT activation. This work adds to a growing body of cell lines in culture that have provided insights into mechanisms of resistance that can be interrogated in primary tumors in patients. In this review, these model systems and their applicability to human cancers, as well as strategies to identify and overcome resistance to TKIs, are discussed.

AB - Tyrosine kinase inhibitors (TKIs) are effective anti-cancer therapies but resistance to these agents eventually develops. Several models of resistance to TKIs have been studied including resistance to EGFR inhibitors. Recent studies in EGFR-dependent A431 cells found upregulation of the IGF1R pathway as a mechanism to overcome blockade of EGFR. This was associated with amplification of IGF1R signaling and recovery of downstream PI3K-AKT activation. This work adds to a growing body of cell lines in culture that have provided insights into mechanisms of resistance that can be interrogated in primary tumors in patients. In this review, these model systems and their applicability to human cancers, as well as strategies to identify and overcome resistance to TKIs, are discussed.

KW - Breast cancer

KW - EGFR

KW - HER2

KW - PI3K

KW - TKI resistance

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=60749085908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60749085908&partnerID=8YFLogxK

U2 - 10.4161/cc.8.1.7324

DO - 10.4161/cc.8.1.7324

M3 - Review article

C2 - 19106609

AN - SCOPUS:60749085908

VL - 8

SP - 18

EP - 22

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 1

ER -